New treatment for Tourette Syndrome

Israel’s Therapix Biosciences is conducting a proof-of-concept Phase II clinical study with the Hannover Medical School, of its lead compound THX-TS01 for 20 patients suffering from Tourette Syndrome.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *